At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Acetazolamidedrug
Likely dose
Acetazolamide 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
C-arm Cone Beam CTA and CTP With Acetazolamide Challenge in Aneurysmal Subarachnoid Hemorrhage: Evaluating Predictability for Early Ischemia in Cerebral Vasospasm
In Brief
A Phase 4 clinical trial evaluating Acetazolamide for Subarachnoid Hemorrhage, Aneurysmal and Vasospasm, Cerebral. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The investigators propose a technique using cone beam CT perfusion (CBCTP) imaging with an acetazolamide challenge as a potential diagnostic tool to detect a defect in cerebral autoregulation at a time when it has not yet caused clinically apparent signs or symptoms. 30 participants will be enrolled at the University of Wisconsin - Madison and can expect to be on study for about 2 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartJul 2019
Primary CompletionJul 2022
TodayJul 2026
First PostedDec 19, 2017
Enrollment StartJul 28, 2019
Primary CompletionJul 15, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.5 years ago
Interventions
Acetazolamidedrug
1 g acetazolamide through a peripheral IV line